Autolus Therapeutics plc

Autolus Therapeutics plc (www.autolus.com) is a clinical-stage biopharmaceutical company. The Company is focused on developing programmed T cell therapies for the treatment of cancer. The Company has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

• Autolus Therapeutics plc